A Novel Restorative Pulmonary Valve Conduit: Early Outcomes of Two Clinical Trials

• Published in: Frontiers in cardiovascular medicine Vol. 7; p. 583360
• Main Authors: Morales, David L, Herrington, Cynthia, Bacha, Emile A, Morell, Victor O, Prodán, Zsolt, Mroczek, Tomasz, Sivalingam, Sivakumar, Cox, Martijn, Bennink, Gerardus, Asch, Federico M
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 04.03.2021
• Subjects: biocompatibility; Cardiovascular Medicine; clinical trial; endogenous tissue restoration; pulmonary valved conduit; RVOT reconstruction; clinical trial; RVOT reconstruction; biocompatibility; pulmonary valved conduit; endogenous tissue restoration
• DOI: 10.3389/fcvm.2020.583360
• ISSN: 2297-055X

We report the first use of a biorestorative valved conduit (Xeltis pulmonary valve-XPV) in children. Based on early follow-up data the valve design was modified; we report on the comparative performance of the two designs at 12 months post-implantation. Twelve children (six male) median age 5 (2 to 12) years and weight 17 (10 to 43) kg, had implantation of the first XPV valve design (XPV-1, group 1; 16 mm ( = 5), and 18 mm ( = 7). All had had previous surgery. Based on XPV performance at 12 months, the leaflet design was modified and an additional six children (five male) with complex malformations, median age 5 (3 to 9) years, and weight 21 (14 to 29) kg underwent implantation of the new XPV (XPV-2, group 2; 18 mm in all). For both subgroups, the 12 month clinical and echocardiographic outcomes were compared. All patients in both groups have completed 12 months of follow-up. All are in NYHA functional class I. Seventeen of the 18 conduits have shown no evidence of progressive stenosis, dilation or aneurysm formation. Residual gradients of >40 mm Hg were observed in three patients in group 1 due to kinking of the conduit ( = 1), and peripheral stenosis of the branch pulmonary arteries ( = 2). In group 2, one patient developed rapidly progressive stenosis of the proximal conduit anastomosis, requiring conduit replacement. Five patients in group 1 developed severe pulmonary valve regurgitation (PI) due to prolapse of valve leaflet. In contrast, only one patient in group 2 developed more than mild PI at 12 months, which was not related to leaflet prolapse. The XPV, a biorestorative valved conduit, demonstrated promising early clinical outcomes in humans with 17 of 18 patients being free of reintervention at 1 year. Early onset PI seen in the XPV-1 version seems to have been corrected in the XPV-2, which has led to the approval of an FDA clinical trial. www.ClinicalTrials.gov, identifier: NCT02700100 and NCT03022708.